Evidence map›Paper›PMID 34707394›Full record

ArticleInternational journal of general medicine2021

Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer.

Nuzhat Sial, Saba Saeed, Mukhtiar Ahmad, Yasir Hameed, Abdul Rehman, Mustansar Abbas, Rizwan Asif, Hamad Ahmed, Muhammad Safdar Hussain, Jalil Ur Rehman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. TMED family genes and their roles in human diseases.International journal of medical sciences · 2023
    Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nuzhat SialDepartment of Zoology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Saba SaeedDepartment of Zoology, University of the Punjab, Lahore, Pakistan.ORCID 0000-0002-0452-8027
Mukhtiar AhmadDepartment of Biochemistry and Biotechnology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Yasir HameedDepartment of Biochemistry and Biotechnology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.ORCID 0000-0002-6378-1962
Abdul RehmanDepartment of Eastern Medicine, Qarshi University, Lahore, Pakistan.
Mustansar AbbasDepartment of Eastern Medicine, Government College University Faisalabad, Faisalabad, Pakistan.
Rizwan AsifDepartment of Microbiology, Government College University Faisalabad, Faisalabad, Pakistan.
Hamad AhmedDepartment of Eastern Medicine, Government College University Faisalabad, Faisalabad, Pakistan.
Muhammad Safdar HussainDepartment of Biochemistry and Biotechnology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Jalil Ur RehmanUniversity College of Conventional Medicine, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Muhammad AtifUniversity College of Conventional Medicine, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Muhammad Rashid KhanUniversity College of Eastern Medicine, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCancer is one of the most common malignancies and the leading cause of death worldwide. As a member of the transmembrane emp24 domain (Tmed)/p24 family of proteins, TMED2 expression variations have been documented earlier in only a few subtypes of human cancers, and the multi-omics profiling of TMED2 as a shared biomarker in different other subtypes of human cancers remains to be uncovered.

methodsIn the current study, TMED2 multi-omics analysis in 24 major subtypes of human cancer was performed using different authentic online databases and bioinformatics analysis including UALCAN, Kaplan-Meier (KM) plotter, Human Protein Atlas (HPA), GENT2, MEXPRESS, cBioportal, STRING, DAVID, TIMER, and CTD.

resultsIn general, the TMED2 expression in 24 major subtypes of human cancers was higher relative to normal controls and was also strongly associated with the lower overall survival (OS) and relapse-free survival (RFS) duration of CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients. This implies that TMED2 plays a significant role in the development and progression of these cancers. Furthermore, the TMED2 overexpression was also correlated with different clinicopathological features of CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients. TMED2-associated genes network was involved in 3 diverse pathways, and finally, few stronger correlations were also explored between TMED2 expression and its promoter methylation level, genetic alterations, and CD8+ T immune cells level.

conclusionIn conclusion, via this in silico study, we have elucidated that TMED2 can serve as a shared diagnostic and prognostic biomarker in CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients of different clinicopathological features but, further in vitro and in vivo research should be carried out to confirm these findings.

Indexed as

biomarkercancerexpression variationsTMED2

Identifiers

PMID34707394
PMCPMC8544130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.